The tissue is the issue: personalized medicine for non-small cell lung cancer.

Hirsch, Fred R; Wynes, Murry W; Gandara, David R; Bunn, Paul A · Clin Cancer Res · 2010

review · Level V

Where this comes from

Abstract

The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed.

Medical subject headings